Crinetics Pharmaceuticals, Inc. (CRNX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Crinetics Pharmaceuticals, Inc. (CRNX) Healthcare & Pipeline Overview

Crinetics Pharmaceuticals, Inc. is a clinical-stage biotechnology company specializing in novel oral therapeutics for rare endocrine diseases and endocrine-related tumors. With its lead candidate, Paltusotine, having completed Phase III for acromegaly, the company focuses on addressing unmet medical needs through its targeted somatostatin receptor and ACTH antagonist programs, aiming to deliver oral treatment options.

What Is the Investment Thesis for CRNX?

Crinetics Pharmaceuticals, Inc. presents an investment thesis centered on its advanced clinical pipeline, particularly Paltusotine, which has completed Phase III trials for acromegaly. This oral selective nonpeptide somatostatin receptor type 2 agonist targets a market currently dominated by injectable treatments, offering a potential significant advantage in patient convenience and adherence. The company's focus on rare endocrine diseases and endocrine-related tumors positions it in high-value, unmet medical need markets. Key growth catalysts include the anticipated regulatory filing and potential approval of Paltusotine for acromegaly, as well as the progression of its earlier-stage candidates, CRN04777 and CRN04894, through clinical development. Financially, as a clinical-stage company, Crinetics exhibits a negative P/E of -8.15 and a profit margin of -2747.2%, alongside a free cash flow of $-0.26 billion, reflecting substantial R&D investment. However, its gross margin of 98.9% suggests strong profitability potential upon commercialization. Risks include the inherent uncertainties of clinical trials, regulatory approval processes, and the significant capital required to bring drugs to market. The company's beta of 0.28 indicates relatively low volatility.

Based on FMP financials and quantitative analysis

CRNX Key Highlights

• Market Capitalization: $3.88 billion, reflecting its valuation as a clinical-stage biotechnology company with a promising pipeline.
• Gross Margin: 98.9%, indicating strong potential profitability on any future revenue, typical for a company with drug candidates and low cost of goods sold prior to commercialization.
• Negative Profit Margin: -2747.2%, characteristic of a clinical-stage company heavily investing in research and development without significant product revenue.
• Free Cash Flow: $-0.26 billion, demonstrating substantial cash burn associated with ongoing clinical trials and R&D activities.
• Lead Product Candidate: Paltusotine has completed Phase III clinical trials for acromegaly, representing a significant advancement towards potential market entry.

Who Are CRNX's Competitors?

CRNX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CRNX's Key Strengths?

• Lead product candidate, Paltusotine, has completed Phase III clinical trials for acromegaly, signaling advanced pipeline maturity.
• Specialized focus on rare endocrine diseases and endocrine-related tumors addresses high-value markets with significant unmet medical needs.
• Expertise in developing oral nonpeptide therapies offers a potential convenience advantage over existing injectable treatments.
• High gross margin of 98.9% indicates strong profitability potential once products are commercialized.

What Are CRNX's Weaknesses?

• Currently unprofitable with a profit margin of -2747.2%, typical for a clinical-stage biotech.
• Significant free cash flow burn of $-0.26 billion due to intensive research and development activities.
• Reliance on the successful outcome of clinical trials and regulatory approvals for future revenue generation.
• No commercialized products yet, meaning no current revenue streams from drug sales.

What Could Drive CRNX Stock Higher?

• Potential regulatory filing for Paltusotine in acromegaly following the successful completion of Phase III trials, moving closer to market authorization.
• Potential regulatory approval of Paltusotine for acromegaly, which would enable commercialization and generate the company's first product revenue.
• Advancement of CRN04777 into later-stage clinical trials for congenital hyperinsulinism, validating its therapeutic potential and progressing the pipeline.
• Advancement of CRN04894 into later-stage clinical trials for Cushing's and congenital adrenal hyperplasia, diversifying the company's therapeutic offerings.
• Continued progress in the development of Paltusotine for additional indications such as carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs), expanding its market potential.

What Are the Key Risks for CRNX?

• Negative return on equity (-44.0%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• High R&D expenses and significant cash burn, evidenced by a free cash flow of $-0.26 billion and a profit margin of -2747.2%, characteristic of a clinical-stage biotechnology company.
• Failure to secure regulatory approval for Paltusotine or other pipeline candidates, which would significantly impact future revenue generation and the company's valuation.
• Clinical trial failures or delays for CRN04777 and CRN04894, preventing their progression to market and limiting future growth opportunities.
• Intense competition from existing therapies or other companies developing treatments for rare endocrine diseases, potentially impacting market share and pricing power.
• Challenges in successfully commercializing approved products, including market access, pricing negotiations, and achieving broad physician adoption.

What Are the Growth Opportunities for CRNX?

• Paltusotine for Acromegaly Commercialization: The successful completion of Phase III clinical trials for Paltusotine in acromegaly represents Crinetics' most immediate and significant growth driver. The global market for acromegaly treatments, currently dominated by injectable somatostatin analogs, offers substantial revenue potential for an oral therapy. An oral option like Paltusotine could capture significant market share by offering improved patient convenience, potentially leading to better adherence and quality of life. The timeline for this opportunity is near-to-medium term, contingent on successful regulatory approval and a robust commercial launch strategy, which would transition Crinetics into a commercial-stage company.
• Paltusotine for Carcinoid Syndrome and NETs Expansion: Beyond acromegaly, Paltusotine has completed Phase II clinical trials for carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). These are also rare diseases with considerable unmet needs, representing additional, distinct market segments for the same lead compound. Expanding the indications for Paltusotine would significantly broaden its addressable patient population and revenue potential, leveraging the substantial investment already made in its development. The development timeline for these additional indications would follow regulatory pathways post-Phase II, potentially offering medium-term growth and diversifying the drug's market impact.
• CRN04777 for Congenital Hyperinsulinism Development: Crinetics' CRN04777, an oral selective somatostatin type 5 receptor agonist, is currently in Phase I for congenital hyperinsulinism. This rare genetic disorder causes severe hypoglycemia, particularly in infants and children, with limited effective treatment options. Developing a novel oral therapy for this vulnerable pediatric population could address a critical unmet need. Successful progression through clinical trials would unlock a new, distinct market opportunity, albeit with a longer development timeline. This program highlights Crinetics' commitment to addressing rare diseases with innovative, targeted approaches for long-term growth.
• CRN04894 for Cushing's and Congenital Adrenal Hyperplasia: The development of CRN04894, an oral adrenocorticotrophic hormone (ACTH) antagonist, in Phase I for Cushing's disease and congenital adrenal hyperplasia, represents another significant growth avenue. These are chronic endocrine disorders requiring lifelong management, and an oral ACTH antagonist could offer a substantial therapeutic improvement over existing treatments. The market for these conditions, while rare, is high-value. Advancing this candidate through clinical development would further diversify Crinetics' pipeline, targeting additional high-need patient populations and contributing to the company's long-term growth trajectory.
• Pipeline Expansion and Novel Drug Discovery: Crinetics' core scientific expertise lies in the discovery and development of nonpeptide agonists for endocrine receptors. This robust platform positions the company for continuous future pipeline expansion. Ongoing investment in research and development to identify new targets and develop additional drug candidates for other rare endocrine diseases or endocrine-related tumors could provide sustained long-term growth. This strategy ensures a continuous stream of potential products beyond the current lead candidates, leveraging the company's specialized scientific capabilities and maintaining its innovative edge in the therapeutic area.

What Opportunities Does CRNX Have?

• Potential regulatory approval and successful commercialization of Paltusotine for acromegaly, transitioning the company to a commercial stage.
• Expansion of Paltusotine's indications to include carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs), broadening its market reach.
• Advancement of early-stage pipeline candidates, CRN04777 and CRN04894, through clinical development to address additional rare endocrine disorders.
• Potential for strategic partnerships or licensing agreements to accelerate development, commercialization, or expand geographic reach.

What Threats Does CRNX Face?

• Risk of clinical trial failures or delays for pipeline candidates, which could significantly impact future prospects and valuation.
• Challenges in navigating complex regulatory approval processes, potentially delaying or preventing market entry.
• Intense competition from larger pharmaceutical companies and other biotechs developing treatments for endocrine disorders.
• Intellectual property challenges and the risk of patent expiration affecting market exclusivity.
• Ongoing need for significant capital to fund R&D and commercialization efforts, posing potential funding risks.

What Are CRNX's Competitive Advantages?

• Proprietary drug candidates, such as Paltusotine, CRN04777, and CRN04894, targeting specific endocrine receptors with novel mechanisms of action.
• Strategic focus on rare diseases, which often benefit from orphan drug designations, potentially leading to extended market exclusivity and reduced competition.
• Development of oral nonpeptide therapies, offering a significant convenience advantage and potentially improved patient adherence over existing injectable or infused treatments.
• Specialized scientific expertise in endocrine drug discovery and development, fostering a focused and innovative R&D pipeline in a niche therapeutic area.

What Does CRNX Do?

Crinetics Pharmaceuticals, Inc., incorporated in 2008 and headquartered in San Diego, California, is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics for rare endocrine diseases and endocrine-related tumors. The company's strategic focus is on addressing significant unmet medical needs through novel drug candidates. Its most advanced product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist. Paltusotine has successfully completed Phase III clinical trials for the treatment of acromegaly, a chronic disorder caused by excessive growth hormone production, positioning it as a potential oral alternative to current injectable therapies. Furthermore, Paltusotine has also completed Phase II clinical trials for the treatment of carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs), indicating its broader potential across multiple endocrine-related conditions. Beyond its lead candidate, Crinetics is actively developing a robust pipeline of early-stage assets. This includes CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is currently in Phase I clinical trials for the treatment of congenital hyperinsulinism, a rare genetic disorder causing severe hypoglycemia. Additionally, the company is advancing CRN04894, an oral adrenocorticotrophic hormone (ACTH) antagonist, also in Phase I clinical trials, targeting Cushing's disease and congenital adrenal hyperplasia. With a team of 437 employees, Crinetics Pharmaceuticals, Inc. maintains a strong commitment to pioneering oral therapies that could offer improved patient convenience and adherence compared to traditional injectable treatments, thereby enhancing the quality of life for patients with these challenging and often debilitating conditions.

What Products and Services Does CRNX Offer?

• Discovers and develops oral therapeutics for rare endocrine diseases.
• Focuses on endocrine-related tumors, including carcinoid syndrome and neuroendocrine tumors.
• Lead product candidate, Paltusotine, is an oral selective nonpeptide somatostatin receptor type 2 agonist.
• Paltusotine has completed Phase III clinical trials for acromegaly, a chronic endocrine disorder.
• Paltusotine has completed Phase II clinical trials for carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).
• Developing CRN04777, an oral selective somatostatin type 5 receptor agonist, for congenital hyperinsulinism (Phase I).
• Developing CRN04894, an oral adrenocorticotrophic hormone (ACTH) antagonist, for Cushing's and congenital adrenal hyperplasia (Phase I).
• Aims to commercialize novel, orally administered treatments for conditions with significant unmet medical needs.

How Does CRNX Make Money?

• Primarily focused on the research, development, and clinical testing of novel drug candidates for rare endocrine diseases.
• Aims to generate revenue through the eventual commercialization and sale of approved pharmaceutical products.
• May pursue strategic partnerships, licensing agreements, or collaborations for drug development, manufacturing, and commercialization to leverage external expertise and resources.
• Relies on significant capital investment to fund extensive preclinical and clinical trials required to advance pipeline assets through regulatory approval processes.

What Industry Does CRNX Operate In?

Crinetics Pharmaceuticals, Inc. operates within the highly specialized Biotechnology industry, specifically targeting rare endocrine diseases and endocrine-related tumors. This segment of the healthcare sector is characterized by a strong emphasis on research and development, high regulatory hurdles, and significant unmet medical needs. Current market trends include a growing focus on orphan drug development, driven by regulatory incentives and the potential for premium pricing due to limited treatment options. There is also an increasing demand for oral therapies that can improve patient convenience and adherence compared to traditional injectable or infused treatments. Crinetics positions itself by developing novel oral nonpeptide agonists, aiming to differentiate its offerings in a competitive landscape that includes both established pharmaceutical giants and other clinical-stage biotechs. The company's strategy to address niche markets with high-value therapeutics places it as a key innovator in the rare endocrine disease space, seeking to disrupt existing treatment paradigms.

Who Are CRNX's Key Customers?

• Patients diagnosed with rare endocrine diseases such as acromegaly, congenital hyperinsulinism, Cushing's disease, and congenital adrenal hyperplasia.
• Patients suffering from endocrine-related tumors, specifically carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).
• Healthcare providers, including endocrinologists, oncologists, pediatric specialists, and other physicians who diagnose and treat these specific conditions.
• Hospitals, specialized clinics, and pharmacies that administer, dispense, or facilitate access to these highly specialized therapeutics.

How Crinetics Pharmaceuticals, Inc. Is Valued

Crinetics Pharmaceuticals, Inc. carries a market capitalization of $8.88B, placing it in the mid-cap category. Relative to its peer group, CRNX's quantitative score of 26/100 is below the peer average of 55/100.

Company Profile

Crinetics Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO R. Scott Struthers. CRNX has traded publicly since 2018.

ROE -44%Key Financial Metrics

Return on equity for Crinetics Pharmaceuticals, Inc. stands at -44.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -35.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -10.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 18.60 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -12.7%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

Crinetics Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 42.50 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Crinetics Pharmaceuticals, Inc. revenue of about $68.5M for fiscal 2026, with EPS near $-4.73. The estimate reflects 10 contributing analysts.

Net buyingInsider Activity

Over the past six months, Crinetics Pharmaceuticals, Inc. insiders filed 15 SEC Form 4 transactions — 1 sales and 14 purchases. On net that is roughly 107K shares acquired (about $2.3M) — insiders putting money in tends to read as conviction.

CRNX Financials

CRNX Latest News

CRNX Analyst Consensus

CRNX MoonshotScore

Latest Crinetics Pharmaceuticals, Inc. Analysis

What Investors Ask About Crinetics Pharmaceuticals, Inc. (CRNX) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources